Oyster Point Pharma to Participate in the 41st Annual Cowen Healthcare Conference
Oyster Point Pharma, a clinical-stage biopharmaceutical company, announced its participation in the 41st Annual Cowen Healthcare Conference on March 2, 2021, at 11:10 a.m. ET. The company focuses on developing innovative therapies for ocular surface diseases, including its lead product candidate, OC-01 (varenicline) nasal spray, aimed at treating dry eye disease. OC-01 activates the trigeminal parasympathetic pathway to enhance natural tear production. This investigational product has yet to be approved.
- None.
- None.
PRINCETON, N.J., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases, today announced that the Company will participate virtually in the 41st Annual Cowen Healthcare Conference on Tuesday, March 2, 2021, at 11:10 a.m. ET, and host investor meetings.
To access the live webcast, please visit the “Investors and News” section of the Oyster Point Pharma website at https://investors.oysterpointrx.com/.
About Oyster Point Pharma, Inc.
Oyster Point Pharma is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases. Oyster Point Pharma’s lead product candidate, OC-01 (varenicline) nasal spray, a highly selective cholinergic agonist, is being developed as a nasal spray to treat the signs and symptoms of dry eye disease. In pre-clinical and clinical studies, OC-01 (varenicline) nasal spray was shown to have a novel mechanism of action via activation of the trigeminal parasympathetic pathway to stimulate the glands and cells responsible for natural tear film production, known as the lacrimal functional unit. OC-01 (varenicline) nasal spray is an investigational new drug and has not been approved for any use in any country. The safety and efficacy of OC-01 (varenicline) nasal spray have not previously been established.
Investor Contact:
Tim McCarthy
LifeSci Advisors, LLC
(212) 915-2564
investors@oysterpointrx.com
Media Contact:
Sheryl Seapy
W2O Group
(213) 262-9390
sseapy@w2ogroup.com
FAQ
When is Oyster Point Pharma participating in the Cowen Healthcare Conference?
What is the main focus of Oyster Point Pharma?
What is OC-01 (varenicline) nasal spray?
Is OC-01 (varenicline) nasal spray approved?
How can I access the webcast of the conference?
